Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: phase II returned 20 record(s)
|
|
Tuesday, 07/31/2018
|
Use of Modified Risk Function in Drug Intervention Planning
Myung Shin Sim, UCLA
|
A Confirmatory Basket Trial Design for Multiple Tumor Types Based on Conditional Power
Huiling Li; Jianming Wang, Celgene Corporation; Yeongjin Gwon, University of Connecticut; Xiaolong Luo, Celgene Corporation
9:05 AM
|
A Note on Phase II Single-Arm Two-Stage Designs for Safety
Seongho Kim, Wayne State University; Weng Kee Wong, UCLA
10:50 AM
|
Biomarker-Defined Subgroup Selection Adaptive Design for Phase III Confirmatory Trial
Rui Tang, Shire; Xiaoye Ma, University of Minnesota; Hui Yang, Amgen Inc.
11:50 AM
|
|
Wednesday, 08/01/2018
|
A Stagewise Prognostic Control Predictive Approach (SPCPA) for Subgroup Identification and Its Application in a Phase II Study
Wanying Li, Gilead Sciences; Wangshu Zhang, Gilead Sciences; Lovely Goyal, Gilead Sciences; Yuanyuan Xiao, Gilead Sciences
|
Single Item Analysis of Patient-Reported Outcome Measures in a Phase III Randomized Controlled Trial
Stacie Hudgens, Clinical Outcome Solutions; Lysbeth Floden, Clinical Outcome Solutions
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
|
A Stagewise Prognostic Control Predictive Approach (SPCPA) for Subgroup Identification and Its Application in a Phase II Study
Wanying Li, Gilead Sciences; Wangshu Zhang, Gilead Sciences; Lovely Goyal, Gilead Sciences; Yuanyuan Xiao, Gilead Sciences
8:35 AM
|
Single Item Analysis of Patient-Reported Outcome Measures in a Phase III Randomized Controlled Trial
Stacie Hudgens, Clinical Outcome Solutions; Lysbeth Floden, Clinical Outcome Solutions
9:00 AM
|
Controlling the Family-Wise Type I Error Rate in a Phase II POC Trial of the Merck Pneumococcal Vaccine Program: An Application of the Hochberg Approach
Jianing Li, Merck Research Lab
9:35 AM
|
A Biomarker-Directed Phase 2 Oncology Umbrella Trial to Target Combination Therapy in NSCLC
Hua Ma, Merck; Robin Mogg, Merck Research Laboratories
9:35 AM
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
9:50 AM
|
Evaluating the Statistical Properties of Bayesian Basket Trial Designs
Kristen May Cunanan, Memorial Sloan Kettering Cancer Center; Alexia Iasonos, Memorial Sloan Kettering Cancer Center; Ronglai Shen, Memorial Sloan-Kettering Cancer Center; Colin B Begg, Memorial Sloan Kettering Cancer Center; Mithat Gonen, Memorial Sloan Kettering Cancer Center
10:35 AM
|
How the ICH E9 Addendum Influenced a Phase III Clinical Trial with a Radiographic Endpoint
Ruvie Martin, Novartis Pharmaceuticals
11:50 AM
|
|
Thursday, 08/02/2018
|
Bias-Corrected Estimation of Treatment Effects in Biomarker-Based Adaptive Subgroup Analysis: New Approach Based on Randomized Tests with Smooth Rejection Function
Kiichiro Toyoizumi, Shionogi Inc.; Shigeyuki Matsui, Nagoya University
11:05 AM
|
Shewhart-Type Charts in Some Nonstandard Situations: Phase I and Phase II
Yuhui Yao, University of Alabama; Subhabrata Chakraborti, University of Alabama
11:05 AM
|
Adjustment for Phase II S^2 Chart Control Limits Based on Tolerance Intervals
Martin Guillermo Cornejo Sarmiento, Pontifical Catholic University of Rio de Janeiro; Subhabrata Chakraborti, University of Alabama; Eugenio Kahn Epprecht, Pontifical Catholic University of Rio de Janeiro
11:20 AM
|
Biomarker Guided Phase II Two-Stage Design for Targeted Therapy
Zheyu Wang, Johns Hopkins University; Fujun Wang, Medimmune; Chenguang Wang, Johns Hopkins University; Gary Rosner, Johns Hopkins University; Jianliang Zhang, Medimmune; Hao Wang, Johns Hopkins University; Li Shi, Medimmune
11:25 AM
|
|
|
